首页> 外文期刊>Current molecular medicine >Chemoprevention gene therapy (CGT): Novel combinatorial approach for preventing and treating pancreatic cancer
【24h】

Chemoprevention gene therapy (CGT): Novel combinatorial approach for preventing and treating pancreatic cancer

机译:化学预防基因疗法(CGT):预防和治疗胰腺癌的新型组合方法

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Pancreatic cancer remains one of the deadliest of all cancers despite aggressive surgical treatment combined with adjuvant radiotherapy and chemotherapy. Chemoresistance and radioresistance are the principal causes of failure of pancreatic cancer patients to respond to therapy. Conditionally replication-competent adenovirus (CRCA)-based cancer gene therapy is an innovative strategy for treating cancers displaying inherent resistance to treatment. Limitations of current adenovirus (Ad)-based gene therapies for malignant tumors include lack of cancer-specificity, and effective and targeted delivery. To remedy this situation, CRCAs have been designed that express E1A, necessary for Ad replication, under the control of a cancer-specific progression elevated gene-3 promoter (PEG-Prom) with concomitant expression of an immunomodulatory cytokine, such as mda-7/IL-24 or interferon-γ(IFN-γ, under the control of a ubiquitous and strong cytomegalovirus promoter (CMV-Prom) from the E3 region. These bipartite CRCAs, when armed with a transgene, are called cancer terminator viruses (CTVs), i.e., Ad.PEG-E1A-CMV-mda-7 (CTV-M7) and Ad.PEG-E1A-CMV-IFN-γ(CTV-γ), because of their universal effectiveness in cancer treatment irrespective of p53/pRb/p16 or other genetic alterations in tumor cells. In addition to their selective oncolytic effects in tumor cells, the potent 'bystander antitumor properties of MDA-7/IL-24 and IFN-γ embody the CTVs with expanded treatment properties for both primary and distant cancers. Pancreatic cancer cells display a "translational block" of mda-7/ IL-24 mRNA, limiting production of MDA-7/IL-24 protein and cancer-specific apoptosis. Specific chemopreventive agents abrogate this "translational block" resulting in pancreatic cancer-specific killing. This novel chemoprevention gene therapy (CGT) strategy holds promise for both prevention and treatment of pancreatic cancers where all other strategies have proven ineffective.
机译:尽管进行了积极的外科治疗以及辅助放疗和化疗,胰腺癌仍然是所有癌症中最致命的癌症之一。化学抗性和放射抗性是胰腺癌患者对治疗失败的主要原因。基于条件复制能力的腺病毒(CRCA)的癌症基因疗法是一种创新的策略,用于治疗表现出固有抗药性的癌症。当前基于腺病毒(Ad)的用于恶性肿瘤的基因治疗的局限性包括缺乏癌症特异性以及有效且靶向的递送。为了解决这种情况,已经设计了在癌特异性进展升高的基因3启动子(PEG-Prom)的控制下表达E1A(Ad复制所必需的)的CRCA,并伴随表达免疫调节性细胞因子,例如mda-7。 / IL-24或干扰素-γ(IFN-γ)在E3区普遍存在的强巨细胞病毒启动子(CMV-Prom)的控制下。这些带有转移基因的二联CRCA被称为癌症终结者病毒(CTV) ),即Ad.PEG-E1A-CMV-mda-7(CTV-M7)和Ad.PEG-E1A-CMV-IFN-γ(CTV-γ),因为它们在癌症治疗中具有通用性,而与p53 / pRb / p16或肿瘤细胞中的其他遗传改变除了MDA-7 / IL-24和IFN-γ的强大的“旁观者”抗肿瘤特性外,它们在肿瘤细胞中的选择性溶瘤作用还体现了CTV的扩展治疗特性胰腺癌细胞显示出mda-7 / IL-24 mRNA的“翻译阻滞”,产生MDA-7 / IL-24蛋白和癌症特异性凋亡。特定的化学预防药物消除了这种“翻译阻滞”,从而导致了胰腺癌的特异性杀伤。这种新颖的化学预防基因治疗(CGT)策略在所有其他策略均无效的情况下,对于胰腺癌的预防和治疗具有广阔的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号